{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:12:19Z","timestamp":1792001539730,"version":"4.4.0"},"reference-count":45,"publisher":"American Diabetes Association","issue":"6","license":[{"start":{"date-parts":[[2019,5,20]],"date-time":"2019-05-20T00:00:00Z","timestamp":1558310400000},"content-version":"vor","delay-in-days":103,"URL":"http:\/\/www.diabetesjournals.org\/content\/license"}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,6,1]]},"abstract":"<jats:p>Sodium\u2013glucose cotransporter (SGLT) inhibitors are new oral antidiabetes medications shown to effectively reduce glycated hemoglobin (A1C) and glycemic variability, blood pressure, and body weight without intrinsic properties to cause hypoglycemia in people with type 1 diabetes. However, recent studies, particularly in individuals with type 1 diabetes, have demonstrated increases in the absolute risk of diabetic ketoacidosis (DKA). Some cases presented with near-normal blood glucose levels or mild hyperglycemia, complicating the recognition\/diagnosis of DKA and potentially delaying treatment. Several SGLT inhibitors are currently under review by the U.S. Food and Drug Administration and European regulatory agencies as adjuncts to insulin therapy in people with type 1 diabetes. Strategies must be developed and disseminated to the medical community to mitigate the associated DKA risk. This Consensus Report reviews current data regarding SGLT inhibitor use and provides recommendations to enhance the safety of SGLT inhibitors in people with type 1 diabetes.<\/jats:p>","DOI":"10.2337\/dc18-2316","type":"journal-article","created":{"date-parts":[[2019,2,6]],"date-time":"2019-02-06T18:45:22Z","timestamp":1549478722000},"page":"1147-1154","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":340,"title":["International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium\u2013Glucose Cotransporter (SGLT) Inhibitors"],"prefix":"10.2337","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0773-6961","authenticated-orcid":false,"given":"Thomas","family":"Danne","sequence":"first","affiliation":[{"name":"Diabetes Centre for Children and Adolescents, Kinder- und Jugendkrankenhaus Auf der Bult, Hannover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satish","family":"Garg","sequence":"additional","affiliation":[{"name":"University of Colorado Denver and Barbara Davis Center for Diabetes, Aurora, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne L.","family":"Peters","sequence":"additional","affiliation":[{"name":"Keck School of Medicine of the University of Southern California, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9723-3876","authenticated-orcid":false,"given":"John B.","family":"Buse","sequence":"additional","affiliation":[{"name":"University of North Carolina School of Medicine, Chapel Hill, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6099-2406","authenticated-orcid":false,"given":"Chantal","family":"Mathieu","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, UZ Gasthuisberg, KU Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5999-0091","authenticated-orcid":false,"given":"Jeremy H.","family":"Pettus","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Medicine, University of California, San Diego, San Diego, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles M.","family":"Alexander","sequence":"additional","affiliation":[{"name":"Alexander Associates LLC, Gwynedd Valley, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0273-4732","authenticated-orcid":false,"given":"Tadej","family":"Battelino","sequence":"additional","affiliation":[{"name":"Department of Pediatric Endocrinology, Diabetes and Metabolic Diseases, University Children\u2019s Hospital, University Medical Centre Ljubljana, and Faculty of Medicine, University of Ljubljana, Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. Javier","family":"Ampudia-Blasco","sequence":"additional","affiliation":[{"name":"Clinic University Hospital of Valencia, Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9998-055X","authenticated-orcid":false,"given":"Bruce W.","family":"Bode","sequence":"additional","affiliation":[{"name":"Atlanta Diabetes Associates, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1580-8040","authenticated-orcid":false,"given":"Bertrand","family":"Cariou","sequence":"additional","affiliation":[{"name":"Clinique d'endocrinologie, L'institut du thorax, CHU Nantes, CIC 1413 INSERM, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly L.","family":"Close","sequence":"additional","affiliation":[{"name":"The diaTribe Foundation, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7055-2084","authenticated-orcid":false,"given":"Paresh","family":"Dandona","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes and Metabolism, University at Buffalo, The State University of New York, Buffalo, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjoy","family":"Dutta","sequence":"additional","affiliation":[{"name":"JDRF International, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1384-1584","authenticated-orcid":false,"given":"Ele","family":"Ferrannini","sequence":"additional","affiliation":[{"name":"National Research Council (CNR) Institute of Clinical Physiology, Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5153-8324","authenticated-orcid":false,"given":"Spiros","family":"Fourlanos","sequence":"additional","affiliation":[{"name":"Department of Diabetes and Endocrinology, Royal Melbourne Hospital, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Grunberger","sequence":"additional","affiliation":[{"name":"Grunberger Diabetes Institute, Bloomfield Hills, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2425-9565","authenticated-orcid":false,"given":"Simon R.","family":"Heller","sequence":"additional","affiliation":[{"name":"Academic Unit of Diabetes, Endocrinology & Metabolism, University of Sheffield, Sheffield, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4821-0117","authenticated-orcid":false,"given":"Robert R.","family":"Henry","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Medicine, University of California, San Diego, San Diego, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin J.","family":"Kurian","sequence":"additional","affiliation":[{"name":"Close Concerns, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3646-1744","authenticated-orcid":false,"given":"Jake A.","family":"Kushner","sequence":"additional","affiliation":[{"name":"McNair Interests, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tal","family":"Oron","sequence":"additional","affiliation":[{"name":"Jesse Z and Sara Lea Shafer Institute of Endocrinology and Diabetes, National Center for Childhood Diabetes, Schneider Children\u2019s Medical Center of Israel, Petah Tikva, Israel"},{"name":"Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6838-5355","authenticated-orcid":false,"given":"Christopher G.","family":"Parkin","sequence":"additional","affiliation":[{"name":"CGParkin Communications, Inc., Boulder City, NV"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas R.","family":"Pieber","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Graz, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6187-8445","authenticated-orcid":false,"given":"Helena W.","family":"Rodbard","sequence":"additional","affiliation":[{"name":"Endocrine and Metabolic Consultants, Rockville, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desmond","family":"Schatz","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Department of Pediatrics, University of Florida, Gainesville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay S.","family":"Skyler","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Diabetes and Metabolism, Miller School of Medicine, University of Miami, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William V.","family":"Tamborlane","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Yale School of Medicine, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3033-4813","authenticated-orcid":false,"given":"Koutaro","family":"Yokote","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Metabolism and Endocrinology, Chiba University Graduate School of Medicine, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6616-5612","authenticated-orcid":false,"given":"Moshe","family":"Phillip","sequence":"additional","affiliation":[{"name":"Jesse Z and Sara Lea Shafer Institute of Endocrinology and Diabetes, National Center for Childhood Diabetes, Schneider Children\u2019s Medical Center of Israel, Petah Tikva, Israel"},{"name":"Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2019,2,6]]},"reference":[{"key":"2022031223593591800_B1","doi-asserted-by":"crossref","first-page":"750","DOI":"10.4158\/EP.14.6.750","article-title":"Hypoglycemia: still the limiting factor in the glycemic management of diabetes","volume":"14","author":"Cryer","year":"2008","journal-title":"Endocr Pract"},{"key":"2022031223593591800_B2","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.2337\/diacare.17.10.1178","article-title":"Insulin omission in women with IDDM","volume":"17","author":"Polonsky","year":"1994","journal-title":"Diabetes Care"},{"key":"2022031223593591800_B3","doi-asserted-by":"crossref","first-page":"754","DOI":"10.2337\/diacare.18.6.754","article-title":"Assessment of diabetes-related distress","volume":"18","author":"Polonsky","year":"1995","journal-title":"Diabetes Care"},{"key":"2022031223593591800_B4","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1185\/03007990903073654","article-title":"Epidemiology and correlates of weight worry in the multinational Diabetes Attitudes, Wishes and Needs study","volume":"25","author":"Peyrot","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"2022031223593591800_B5","unstructured":"U.S. Food and Drug Administration. FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood [Internet], 15 May 2015. Available from https:\/\/www.fda.gov\/downloads\/drugs\/drugSafety\/ucm446954.pdf. Accessed 25 May 2018"},{"key":"2022031223593591800_B6","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med"},{"key":"2022031223593591800_B7","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"2022031223593591800_B8","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"2022031223593591800_B9","doi-asserted-by":"crossref","first-page":"771","DOI":"10.2337\/dc16-2724","article-title":"Renal handling of ketones in response to sodium\u2013glucose cotransporter 2 inhibition in patients with type 2 diabetes","volume":"40","author":"Ferrannini","year":"2017","journal-title":"Diabetes Care"},{"key":"2022031223593591800_B10","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"2022031223593591800_B11","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.2337\/dc17-0403","article-title":"Use of adjuvant pharmacotherapy in type 1 diabetes: international comparison of 49,996 individuals in the prospective diabetes follow-up and T1D Exchange registries","volume":"40","author":"Lyons","year":"2017","journal-title":"Diabetes Care"},{"key":"2022031223593591800_B12","unstructured":"Astellas Pharma. Approval of Suglat tablets, selective SGLT2 inhibitor, for additional indication of type 1 diabetes mellitus and additional dosage and administration in Japan. Press release [Internet], 2018. Available from https:\/\/www.astellas.com\/system\/files\/news\/2018-12\/181221_2_Eg_2.pdf. Accessed 24 December 2018"},{"key":"2022031223593591800_B13","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/S2213-8587(17)30308-X","article-title":"Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial","volume":"5","author":"Dandona","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2022031223593591800_B14","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.2337\/dc18-0623","article-title":"Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 study): 24-week results from a randomized controlled trial","volume":"41","author":"Mathieu","year":"2018","journal-title":"Diabetes Care"},{"key":"2022031223593591800_B15","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.2337\/dc18-1087","article-title":"Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: the DEPICT-1 52-week study","volume":"41","author":"Dandona","year":"2018","journal-title":"Diabetes Care"},{"key":"2022031223593591800_B16","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1007\/s00125-018-4671-6","article-title":"SGLT inhibitor adjunct therapy in type 1 diabetes","volume":"61","author":"McCrimmon","year":"2018","journal-title":"Diabetologia"},{"key":"2022031223593591800_B17","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.2337\/dc18-1749","article-title":"Empagliflozin as adjunctive to insulin therapy in type 1 diabetes: the EASE Trials","volume":"41","author":"Rosenstock","year":"2018","journal-title":"Diabetes Care"},{"key":"2022031223593591800_B18","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1056\/NEJMoa1708337","article-title":"Effects of sotagliflozin added to insulin in patients with type 1 diabetes","volume":"377","author":"Garg","year":"2017","journal-title":"N Engl J Med"},{"key":"2022031223593591800_B19","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2337\/dc16-1353","article-title":"The effect of canagliflozin, a sodium glucose cotransporter 2 inhibitor, on glycemic end points assessed by continuous glucose monitoring and patient-reported outcomes among people with type 1 diabetes","volume":"40","author":"Rodbard","year":"2017","journal-title":"Diabetes Care"},{"key":"2022031223593591800_B20","doi-asserted-by":"crossref","DOI":"10.2337\/db18-212-OR","article-title":"Fifty-two-week efficacy and safety of sotagliflozin, a dual SGLT and SGLT2 inhibitor, as adjunct therapy to insulin in adults with type 1 diabetes (inTandem1)","volume":"67","author":"Buse","year":"2018","journal-title":"Diabetes"},{"key":"2022031223593591800_B21","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.2337\/dc14-2806","article-title":"Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct therapy to insulin in type 1 diabetes","volume":"38","author":"Sands","year":"2015","journal-title":"Diabetes Care"},{"key":"2022031223593591800_B22","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.2337\/dc15-1730","article-title":"Efficacy and safety of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to insulin in patients with type 1 diabetes","volume":"38","author":"Henry","year":"2015","journal-title":"Diabetes Care"},{"key":"2022031223593591800_B23","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1210\/jc.2015-1884","article-title":"SGLT2 inhibitors may predispose to ketoacidosis","volume":"100","author":"Taylor","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031223593591800_B24","first-page":"120","article-title":"The regulation of ketogenesis","volume":"87","author":"Foster","year":"1982","journal-title":"Ciba Found Symp"},{"key":"2022031223593591800_B25","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1172\/JCI107537","article-title":"Effects of glucagon on lipolysis and ketogenesis in normal and diabetic men","volume":"53","author":"Liljenquist","year":"1974","journal-title":"J Clin Invest"},{"key":"2022031223593591800_B26","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.tem.2015.05.011","article-title":"SGLT-2 inhibition and glucagon: cause for alarm?","volume":"26","author":"Kibbey","year":"2015","journal-title":"Trends Endocrinol Metab"},{"key":"2022031223593591800_B27","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.2337\/dc15-1380","article-title":"Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors","volume":"38","author":"Rosenstock","year":"2015","journal-title":"Diabetes Care"},{"key":"2022031223593591800_B28","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1172\/JCI72227","article-title":"Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients","volume":"124","author":"Ferrannini","year":"2014","journal-title":"J Clin Invest"},{"key":"2022031223593591800_B29","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/nm.3828","article-title":"Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion","volume":"21","author":"Bonner","year":"2015","journal-title":"Nat Med"},{"key":"2022031223593591800_B30","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1093\/omcr\/omw061","article-title":"The DKA that wasn\u2019t: a case of euglycemic diabetic ketoacidosis due to empagliflozin","volume":"2016","author":"Candelario","year":"2016","journal-title":"Oxf Med Case Rep"},{"key":"2022031223593591800_B31","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/jdi.12401","article-title":"Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors","volume":"7","author":"Ogawa","year":"2016","journal-title":"J Diabetes Investig"},{"key":"2022031223593591800_B32","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.2337\/dc15-0843","article-title":"Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium\u2013glucose cotransporter 2 inhibition","volume":"38","author":"Peters","year":"2015","journal-title":"Diabetes Care"},{"key":"2022031223593591800_B33","first-page":"451","article-title":"Sodium-glucose linked transporter 2 (SGLT2) inhibitors in the management of type-2 diabetes: a drug class overview","volume":"40","author":"Mosley","year":"2015","journal-title":"P T"},{"key":"2022031223593591800_B34","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.2337\/dc13-2338","article-title":"Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial","volume":"37","author":"Perkins","year":"2014","journal-title":"Diabetes Care"},{"key":"2022031223593591800_B35","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/j.1464-5491.2005.01771.x","article-title":"Sick day management using blood 3-hydroxybutyrate (3-OHB) compared with urine ketone monitoring reduces hospital visits in young people with T1DM: a randomized clinical trial","volume":"23","author":"Laffel","year":"2006","journal-title":"Diabet Med"},{"key":"2022031223593591800_B36","first-page":"E837","article-title":"Evaluation of the accuracy of capillary hydroxybutyrate measurement compared with other measurements in the diagnosis of diabetic ketoacidosis: a systematic review","volume-title":"Int J Environ Res Public Health","author":"Brooke","year":"2016"},{"key":"2022031223593591800_B37","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/dme.12604","article-title":"Utility of ketone measurement in the prevention, diagnosis and management of diabetic ketoacidosis","volume":"32","author":"Misra","year":"2015","journal-title":"Diabet Med"},{"key":"2022031223593591800_B38","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1111\/dme.12136","article-title":"Blood \u03b2-hydroxybutyrate vs. urine acetoacetate testing for the prevention and management of ketoacidosis in type 1 diabetes: a systematic review","volume":"30","author":"Klocker","year":"2013","journal-title":"Diabet Med"},{"key":"2022031223593591800_B39","doi-asserted-by":"crossref","first-page":"530","DOI":"10.3399\/bjgp11X588600","article-title":"Point-of-care blood test for ketones in patients with diabetes: primary care diagnostic technology update","volume":"61","author":"Pl\u00fcddemann","year":"2011","journal-title":"Br J Gen Pract"},{"key":"2022031223593591800_B40","doi-asserted-by":"crossref","first-page":"643","DOI":"10.2337\/dc07-1683","article-title":"Can serum \u03b2-hydroxybutyrate be used to diagnose diabetic ketoacidosis?","volume":"31","author":"Sheikh-Ali","year":"2008","journal-title":"Diabetes Care"},{"key":"2022031223593591800_B41","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1900\/RDS.2016.13.217","article-title":"Blood ketones: measurement, interpretation, limitations, and utility in the management of diabetic ketoacidosis","volume":"13","author":"Dhatariya","year":"2016","journal-title":"Rev Diabet Stud"},{"key":"2022031223593591800_B42","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1089\/dia.2018.0246","article-title":"Strategy for mitigating DKA risk in patients with type 1 diabetes on adjunctive treatment with SGLT inhibitors: a STICH protocol","volume":"20","author":"Garg","year":"2018","journal-title":"Diabetes Technol Ther"},{"key":"2022031223593591800_B43","doi-asserted-by":"crossref","first-page":"3411","DOI":"10.1210\/jc.2013-1589","article-title":"Severe hypoglycemia and diabetic ketoacidosis in adults with type 1 diabetes: results from the T1D Exchange clinic registry","volume":"98","author":"Weinstock","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031223593591800_B44","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.2337\/dc16-2620","article-title":"Poor adherence to ketone testing in patients with type 1 diabetes","volume":"40","author":"Albanese-O\u2019Neill","year":"2017","journal-title":"Diabetes Care"},{"key":"2022031223593591800_B45","unstructured":"Walmart. Health\/Diabetes Care\/Ketone Test Strips [Internet]. Available from https:\/\/www.walmart.com\/browse\/health\/ketone-test-strips\/976760_1231757_3866822. Accessed 21 December 2018"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/42\/6\/1147\/552929\/dc182316.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/42\/6\/1147\/552929\/dc182316.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T21:59:15Z","timestamp":1647122355000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/42\/6\/1147\/36001\/International-Consensus-on-Risk-Management-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,6]]},"references-count":45,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2019,2,6]]},"published-print":{"date-parts":[[2019,6,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc18-2316","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,6]]}}}